

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07K 16/18, C12N 5/20, G01N 33/577, 33/68</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/58364</b>
			<b>(43) International Publication Date:</b> 5 October 2000 (05.10.00)
<b>(21) International Application Number:</b> PCT/IL00/00196			<b>(81) Designated States:</b> AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
<b>(22) International Filing Date:</b> 29 March 2000 (29.03.00)			
<b>(30) Priority Data:</b> 129273 30 March 1999 (30.03.99) IL			
<b>(71) Applicant (for all designated States except US):</b> DIAGNOSTIC TECHNOLOGIES LTD. [IL/IL]; Beit Etgarim, Etgar Street 4, 39120 Tirat HaCarmel (IL).			
<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> PALTIELI, Yoav [IL/IL]; Einstein Street 75, 34602 Haifa (IL). RABINOVITCH, Lev [IL/IL]; Rambam Street 2, 28000 Kiryat Ata (IL).			
<b>(74) Agent:</b> REINHOLD COHN AND PARTNERS; P.O. Box 4060, 61040 Tel Aviv (IL).			<b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> ANTIBODIES TO PLACENTAL PROTEIN 13			
<b>(57) Abstract</b> <p>A monoclonal antibody (Mab) capable of binding Placental Protein 13 (PP-13) is disclosed. Also disclosed are hybridoma clones producing the Mab, an immunoassay using the Mab for measuring the level of PP-13 in a biological fluid, and a kit for measuring the level of PP-13 in a biological fluid.</p>			

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TC	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## ANTIBODIES TO PLACENTAL PROTEIN 13

### FIELD OF THE INVENTION

This invention relates to antibodies raised against a placental protein.

### BACKGROUND OF THE INVENTION

References referred to in the text by a number enclosed by parenthesis  
5 are listed at the end of the specification.

The goal of pregnancy management is the delivery of a mature, healthy infant, without encountering complications which can adversely affect the well being of both the mother and the newborn. A significant percentage of pregnancies are affected by various disorders. Among them are preterm  
10 delivery, intrauterine growth retardation and preeclampsia. These complications negatively impact the outcome of affected pregnancies, at enormous cost both to the patients as well as to the health system.

Placental Protein 13 (PP13) is a protein which was previously isolated from human placental tissue (U.S. 4,500,451 to Bohn, *et al.*, the contents of  
15 which are incorporated herein by reference). The protein was characterized by the following parameters: electrophoretic mobility, isoelectric point, sedimentation coefficient, molecular weight determined by ultracentrifugation. molecular weight determined by SDS-PAGE electrophoresis, extinction coefficient and carbohydrate content. The amino acid composition  
20 (residues per 100 residues) was determined but not the amino acid sequence.

PP13 was used to develop an assay for the early stage detection of three specific pregnancy-related disorders: intrauterine growth retardation, preeclampsia and preterm delivery (U.S. 5,198,366 to Silberman, the contents of which are incorporated herein by reference). Both a  
5 radioimmunoassay (RIA) and an enzyme-linked immunosorbent assay (ELISA) were developed using labeled PP13 and anti PP13 polyclonal antiserum, respectively. However, experimental results were given only for the RIA, and not for the ELISA. No further properties of PP13 are disclosed in the Silberman patent. There have also been reports in the literature  
10 regarding the determination of other placental proteins and their relationship to pregnancy disorders (1-3).

The ELISA fulfils requirements of objectivity, simplicity, sensitivity and specificity previously only attained by radioimmunoassay (4). A methodological comparison of ELISA and RIA reveals several advantages  
15 of the former method:

1. ELISA is absolutely safe and does not require a specially designed laboratory and trained personnel for working with radioactive material.
2. Two-antibody sandwich ELISA is a more sensitive, rapid and  
20 easily quantifiable method.
3. Enzymes are rather stable as compared with radioactive tracers and cause a high level of result reproducibility.
4. The enzymatic activity may be measured easily using the spectrophotometric principle of an ELISA-reader, which is much cheaper  
25 and simpler in handling than a gamma-counter.
5. ELISA is more suitable for automation.

It is therefore desirable to develop an improved ELISA for the determination of PP13 levels.

## SUMMARY OF THE INVENTION

It is an object of the present invention to provide monoclonal antibodies (Mab) capable of binding PP13.

It is a further object of the invention to provide an immunoassay which  
5 measures the level of PP13 in biological fluids.

In one aspect of the invention, there is provided a Mab capable of binding PP13. In particular, the invention provides hybridoma clones selected from the group consisting of clones # 26-2, 27-2-3, 215-28-3, 534-16 and 606-8-11-67, as well as the Mab produced by these clones. These clones have  
10 been deposited in accordance with the Budapest Treaty at the Collection Nationale de Cultures de Microorganismes of the Pasteur Institute of 25, Rue du Docteur Roux, Paris, France. The following are the depository details of the clones:

Clone #	Accession No.	Deposit Date
26-2	I-2134	March 4, 1999
27-2-3	I-2135	March 4, 1999
215-28-3	I-2136	March 4, 1999
534-16	I-2137	March 4, 1999
606-8-11-67	I-2138	March 4, 1999

15 In another aspect of the invention, there is provided an immunoassay for measuring the level of PP-13 in a biological fluid comprising the steps of:  
(a) bringing the fluid into contact with a Mab according to the invention, thereby forming Mab-PP-13 complexes; (b) exposing the complexes to a second antibody linked to a signal-generating molecule, the second antibody  
20 being capable of binding the complexes; and (c) providing conditions conducive to the production of a signal generated by the signal-generating molecule.

In the present specification, the term "*signal-generating molecule*" relates to a molecule capable of generating, either directly or indirectly, a detectable signal. The signal may be, e.g. a radioactive emission or a spectrophotometric absorbance at a specific wavelength. Preferably, the signal  
5 will be a color which can be detected by a spectrophotometric reader. The signal-generating molecule may generate the signal directly, e.g. by reacting itself with a chromogenic substrate, or indirectly, e.g. by binding to another molecule which is able to generate a signal. In a preferred embodiment, the signal-generating molecule is a ligand which generates a signal indirectly by  
10 binding to a ligand-binding molecule which is linked to an enzyme, which in turn catalyzes a reaction resulting in color formation.

The biological fluid may be any fluid which may contain PP13, such as placental extract or blood serum. Preferably, the fluid is blood serum. In one embodiment of this aspect of the invention, the Mab, which binds one site on  
15 PP13, is bound to a solid phase such as a microtiter well or a bead. The second antibody will be capable of binding another site on PP13, and may be polyclonal or monoclonal. In a preferred embodiment, the second antibody is also a Mab according to the invention.

In a further aspect of the invention, there is provided a kit for  
20 measuring the level of PP-13 in a biological fluid comprising: (a) a Mab according to the invention; (b) a second antibody linked to a signal-generating molecule; and (c) PP-13 standard solutions. In a preferred embodiment, the second antibody is also a Mab, as described above. The kit may be used to carry out an immunoassay as described above.

## 25 **BRIEF DESCRIPTION OF THE DRAWINGS:**

In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of

non-limiting example only, with reference to the accompanying drawings, in which:

Fig. 1 shows a SDS-PAGE electrophoresis of mouse anti-PP-13 ascites & IgG (the gel is overloaded for visualization of impurities);

5 Fig. 2 illustrates testing of mouse anti-PP-13 serum in a direct ELISA:

Fig. 3 illustrates classing of anti-PP-13 antibodies in a direct ELISA;

Figs. 4 & 5 illustrate testing of anti-PP-13 antibodies in a sandwich ELISA:

10 Figs. 6-9 illustrate classing of anti-PP-13 antibodies in a direct ELISA (cloning: 2<sup>nd</sup> screening);

Fig. 10 illustrates classing of anti-PP-13 antibodies in a direct ELISA (cloning: 3<sup>rd</sup> screening);

15 Fig. 11 illustrates a two-monoclonal antibody sandwich ELISA in different variants;

Fig. 12 shows a standard curve of PP-13 ELISA (monoclonal sandwich);

Fig. 13 illustrates sensitivity of PP-13 ELISA (monoclonal sandwich);

20 Fig. 14 illustrates a dilution curve of PP-13 in the blood serum (monoclonal sandwich ELISA); and

Fig. 15 illustrates an analytical recovery test of PP-13 (monoclonal sandwich ELISA).

## 25 DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

### MATERIALS AND METHODS

#### (a) Purification of PP-13

PP-13 used in this study was isolated and purified from human

placenta according to the method described by Bohn *et al.* with some modifications. Freshly obtained placenta was stripped of membranes and the maternal outer layer. The inner fetal trophoblast region was chopped into small pieces and homogenized in a blender with about 1.5 liters of DDW for 5 min. All subsequent steps were carried out at 4°C. The pH of the extract was adjusted to 7.0 by adding several drops of concentrated NaOH. The extract was then rehomogenized with a tissue homogenizer (Politron) for 5 min. in batches of 300 ml. The homogenized placental extract was stirred for 30 min. and then centrifuged for 60 min. at 10,000 rpm (Sorval large rotor). The supernatant was saved, supplemented with 0.5M NaCl, 100 mM Tris-HCl, 0.05% Tween 20 and 0.1% NaN<sub>3</sub>, and filtered through depth filters, using a vacuum pump. The filtrate containing PP-13 was collected for the first immunoabsorbance column and stored at -20°C.

A 60 ml bed volume anti-PP-13 immunoabsorbance column (I), containing rabbit anti-PP-13 IgG fraction was equilibrated with buffer A (1M NaCl, 100 mM Tris-HCl, 0.1% NaN<sub>3</sub>, pH 8.0). This column was sufficient to handle the extract of one placenta. The placental extract was loaded onto the column at a flow rate of 4 ml/min. The column was washed with buffer A until the optical density (OD) level reached the baseline. The PP-13 peak was eluted from the column with a 6 M urea solution (treated with 1 mg/10 ml of amberlite ionic exchanger MB-6, 20-50 mesh). The eluted protein solution (about 150 ml) was concentrated by ultrafiltration, using 10 kD MW cut-off disk membranes, to a final volume of 50 ml. At the same time, the buffer was switched to phosphate buffer saline (PBS), containing 0.1% NaN<sub>3</sub>, pH 7.4.

A 60 ml bed volume anti-placental extract negative immunoabsorbance column (II), containing rabbit anti-human placental extract IgG fraction was equilibrated with PBS + 0.1% NaN<sub>3</sub>, pH 7.4. PP-13 enriched extract obtained from column I was loaded onto the column at a



flow rate of 3 ml/min. The unbound protein (about 130 ml) was collected and concentrated using 10 kD MW cut-off disk membranes to a final volume of 40 ml. The column was regenerated with 6M urea solution to remove impurities bound to the column and washed with 5 bed volumes of  
5 PBS + 0.1% sodium azide.

A 56 ml bed volume anti-human globulin negative immunoabsorbance column (III), containing rabbit anti-human alpha-1, beta- and delta-globulins IgG was equilibrated with PBS. The PP-13 concentrated extract obtained from the column II was loaded onto the column III at a  
10 flow rate of 3 ml/min. Unbound protein (about 120 ml) was collected and the column was regenerated with 6M urea solution and washed with PBS. This material was repurified using the first immunoabsorbance column, and then used for gel-filtration chromatography which was performed on a Superdex 75 Hiload 26/60 column. The concentrated PP-13 fraction (about  
15 3 ml) was loaded onto the gel-filtration column equilibrated previously with PBS at a flow rate of 3 ml/min. The column was washed with PBS and fractions of 5 ml each were collected. PP-13 was eluted as a third peak, concentrated to a volume of 1 ml, analyzed for purity by SDS-PAGE electrophoresis (5) and quantitated by the Microbradford method and by  
20 ELISA.

(b) Development of anti-PP-13 monoclonal antibodies

Monoclonal anti-PP-13 antibodies (Mab) were produced in the Weizmann Institute (Israel). Five three-month old female Balb/c mice  
25 (Jackson) were immunized twice with 0.05 mg PP-13 in PBS and complete Freund's adjuvant per injection per mouse (i.d. and s.c.), and twice with PP-13 in PBS without adjuvant. The injections were made into each of the hind-footpads and afterwards at multiple sites at both the sides and back of the mice. The injections were separated by an interval of two weeks. Test

bleeds were carried out 10 days after the third and fourth immunizations.

Three weeks later, two mice having the best response (see results section) received two injections of 0.05 mg PP-13 i.p. during two consecutive days. Five days after the last boost, spleens of those two mice  
5 were removed and 100 million cells from each individual spleen were fused using 41% polyethylene glycol 1500 (Serva, Heidelberg, FRG) with 20 million NSO/1 myeloma line cells kindly provided by C. Milstein (MRC, Cambridge, UK), as described previously (6).

Following fusion, cells were distributed into six microplates (96  
10 wells each) at a concentration of 50,000 viable cells/well. Hybrid cells selected for growth in the presence of HAT were kept in a humidified incubator in the presence of 8% CO<sub>2</sub> in air. The growth medium was Dulbecco's modified Eagle's medium (DMEM high glucose, Gibco) supplemented with 1 mM pyruvate, 2 mM glutamine, penicillin (10  
15 units/ml), streptomycin (0.02 mg/ml) and 15% heat inactivated horse serum (HS, Beit Haemek Biological Industries, Israel). Positive hybrid cultures were weaned out of HAT, cloned by limiting dilution, recloned in soft agar and propagated *in vitro* in large volumes of DMEM-HS or *in vivo* as ascites in pristane-treated (BALB/c x DBA/2) mice.

20 Ascitic fluids produced using the best clones were affinity purified on a protein G column (Sigma, Cat. # P 4691). IgG fractions were collected, dialyzed, concentrated, quantitated and tested in an antibody-capture direct ELISA. Aliquots were biotinylated and tested again in an antibody-capture direct ELISA and in variants of a two-monoclonal Ab sandwich ELISA.  
25 The best combination of antibodies with the highest sensitivity was chosen for development of a two-monoclonal Ab sandwich ELISA.

Antibody-capture direct ELISA was employed for the screening of anti- PP-13 antibodies. Microtiter plates were coated with purified PP-13 and blocked with 1% BSA in PBS. Antisera of test bleeds, hybridoma

culture supernatants or ascitic fluids were applied as a primary antibody. Normal mouse serum (NMS) served as a negative control. AP-goat anti-mouse IgG (Fc) without cross-reactivity with other mouse immunoglobulins (Sigma, Cat. # A 1418) and Biotin-goat anti-mouse IgM  
5 (Zymed Laboratories, Inc., Cat. # 62-6840) were used as the secondary antibodies for determination of antibody class specificity. AP-Extravidin was applied to the microplate wells previously incubated with biotinylated Ab.

After incubation with the substrate, optical density was detected in a  
10 Microplate-reader (BIO-TEK Instruments, Inc.) at 405 nm. Since the affinity of the Ab is closely related to the sensitivity of an assay, monoclonal Ab affinities and ability to work with another Ab as a pair were evaluated using two-antibody sandwich ELISA with rabbit polyclonal anti-PP-13 IgG as a primary Ab. Purified PP-13 served as a standard  
15 solution with concentrations from 0 to 2.0 ng/ ml. Antisera of test bleeds, hybridoma culture supernatants or ascitic fluids were applied as the secondary antibodies. AP-goat anti-mouse IgG was used as detecting Ab. After incubation with the substrate, ELISA plates were scanned in the Microplate- reader at 405 nm.

20

#### (c) Two-monoclonal antibody sandwich ELISA

A two-monoclonal antibody sandwich solid-phase enzyme immunoassay with biotin-extravidin amplification system was established for PP-13 measurement in biological fluids. Highly purified PP-13 from  
25 human placenta was used as a standard and control. Two IgG fractions of purified ascitic fluids showed the best result in the two-antibody sandwich assay test used for ELISA development. The level of their purity was controlled by SDS-PAGE electrophoresis (Fig. 1). One Ab was used for coating of flat bottom 96-well Nunc-microplates while the second served as

a secondary antibody after biotinylation.

ELISA plates were coated with anti-PP-13 IgG in PBS and incubated for 2 hours at room temperature. After incubation the plates were washed 3 times with PBS + 0.05% Tween 20 and blocked with assay buffer (PBS + 1% BSA + 0.05% Tween 20) for 2 hours at room temperature. Afterwards the plates were washed in the same manner. PP-13 standard and controls diluted in pooled male serum/assay buffer (1:3) or unknown specimen (blood serum) diluted in assay buffer (1:3) were loaded and microplates were incubated overnight at room temperature. After this and all the following steps the plates were washed 3 times with assay buffer. Biotin-anti-PP-13 IgG in assay buffer as a secondary Ab was added and the plates were incubated for 2 hours at room temperature. Then ELISA plates were incubated with extravidin- alkaline phosphatase solution (Sigma, Cat. # E 2636) in assay buffer for 2 hours at room temperature. The reaction was developed by adding substrate- chromogen mixture (Sigma, Cat. # 104-105) and the results were detected by an ELISA reader at 405 nm. The amount of standard or unknown antigen was determined as an optical density (OD) of the sample minus blank (pooled male serum/assay buffer, 1:3). A standard curve was established by plotting this data against the known amount of PP-13. 2SD confidence interval of standard curve has been plotted as a basis for the quality control statistics. Results were calculated using Dbase software.

## RESULTS

(a) Testing of anti-PP-13 monoclonal antibodies

(i) Test bleeds

Blood sera obtained from five immunized mice during test bleeds were titrated (1:200 – 1:48600) to monitor the development of the response. Blood samples were checked in antibody capture direct ELISA. Mice # 1, 2,

4 were found to have a strong response: high levels of specific Ab were detected. Titers of antisera from mice # 3 and # 5 were lower (Fig. 2). The same mice showed quite high antibody affinities in sandwich ELISA recognizing different concentrations of PP-13 starting from 50 pg/ml (not shown). Two mice, # 1 and # 2 having the best response, were chosen for the last boost and fusion.

(ii) Screening of tissue culture supernatants (supers)

Tissue culture supers were screened periodically during hybridoma growing by antibody capture ELISA using AP-goat anti-mouse IgG. Positive samples were rescreened using the same secondary Ab and Biotin-goat anti-mouse IgM for identifying the class of Ab. Supers # 12, 26, 27, 59, 79, 140, 215, 249, 409, 442, 489, 502, 531, 534, 606, 669, 676, 808, 882 were rescreened. It was found that Ab # 26, 27, 215, 249, 534, 606, 669, 882 belonged to IgG class, Ab # 12, 59, 79, 489, 502, 531, 676 were classified as IgM and Ab # 140, 409, 442, 808 showed low levels with both secondary Abs (selected results are shown in Fig. 3).

The Ab affinities were evaluated in sandwich ELISA with rabbit anti-PP-13 IgG as a primary Ab. Tissue cultures # 27, 215 and 534 produced Ab with high affinity (selected results are shown in Fig. 4). Tissue cultures # 26, 27, 215, 249, 534, 606, 669, 882 producing Ab of IgG class were chosen for cloning. Their clones were rescreened in the same manner (Figs. 5-10). Taking into consideration the class, level and affinity of Ab, the most stable clones # 26-2, 27-2-3, 215-28-3, 534-16, 606-8-11-67 were used for the induction of ascites:

Clone # 26-2 produced Ab of IgG class with a high level of response.

Clone # 27-2-3 produced Ab of IgG class with high affinity; the detection limit was 0.05 ng/ml of PP-13.

Clone # 215-28-3 produced Ab of IgG class with relatively high response and best affinity, recognizing different concentrations of PP-13

starting from 0.05 ng/ml.

Clone # 534-16 produced Ab of IgG class with relatively high affinity: the detection limit of PP-13 concentration was 0.2 ng/ml.

Clone # 606-8-11-67 produced Ab of IgG class with a high level of  
5 response.

(iii) Purifying and testing ascitic fluids

Five ascites # 26-2, 27-2-3, 215-28-3, 534-16, 606-8-11-67 were affinity purified on a protein G column (Sigma, Cat. # P 4691). Their IgG  
10 fractions were tested in the Ab capture direct ELISA confirming IgG class. Aliquots of these Ab were biotinylated. After labeling, biotin-Ab were checked in the Ab capture direct ELISA, using AP-Extravidin as detecting reagent. All the Abs recognized PP-13 after biotinylation. Two- antibody sandwich assays with different combinations of primary and secondary Ab  
15 were carried out. The most effective variant was found to use IgG # 27-2-3 for coating and Biotin-IgG # 215-28-3 as a secondary Ab (Fig. 11). The sensitivity of this assay was 0.05 ng/ml of PP-13.

(b) Characterization of two-antibody sandwich ELISA

(i) Standard curve statistics

20 Assay conditions of a two-antibody sandwich ELISA were optimized and a standard curve was constructed. Different concentrations of PP-13 were used: 10, 20, 50, 100, 200, 500 pg/ml (Fig. 12). Optical densities of P-13 standard samples minus blank vs. known amount of PP-13 were plotted. An effective range of from 10 to 500 pg/ml PP-13 concentrations  
25 was reliably measured. The standard curve shape was nearly linear; the correlation coefficient between PP-13 concentrations and optical densities was  $r = 0.99$ . The SD of residuals from the line = 0.08, p value < 0.0001 (two tailed). Its slope was quite steep, with a y-axis intercept near 0.

Averaged coefficient of variation of standard curve data points was 5.6%, and 2SD confidence limits were rather narrow.

(ii) Sensitivity of the test

5        This parameter is defined as the minimal detection limit of an assay which is to be determined as the least concentration of PP-13 which can be distinguished from a sample containing no protein. The distinction is based on the confidence limits of the estimate of the zero standard on the one hand, and the standard on the other. It is seen from the graph (Fig. 13) that  
10 10 pg/ml of PP-13 could be clearly distinguished from zero. This is the maximum sensitivity which can be attained using the sandwich ELISA technique.

(iii) Specificity

      The traditional method for detecting any type of non-specificity is an  
15 examination of parallelism between dilutions of specimen and standard. A high level of parallelism has been found between pooled blood serum samples and different concentrations of standard PP-13 solution in dilution experiment. Series of pooled serum dilutions has been made: 1:2, 1:4, 1:8 and 1:16. Normalized data points of blood serum and standard PP-13  
20 solution were plotted (Fig. 14). Correlation between two dilution curves was calculated. The slope of pooled serum curve was = 1.02; correlation coefficient  $r = 0.9998$ ; SD of residuals from the line = 2.79; p value < 0.0001 (two tailed).

(iv) Analytical recovery test

25        This test is based on determination of known concentrations of PP-13 in a blood serum. Pooled blood serum from pregnant women was supplemented with four known amounts of PP-13: 20, 50, 100 and 200 pg/ml and analyzed together with the same concentrations of PP-13 control

pool. The data points were plotted on a graph (Fig. 15). The overall analytical recovery was found to be 106.2% and the curve was linear with the slope = 1.03. Correlation between estimated PP-13 levels in pooled blood serum and in the control pool was very strong ( $r = 1$ ).

#### 5 (v) Intra- and inter-assay variation

These parameters were used for evaluation of an assay precision. Intra-assay variation was assessed as the coefficient of variation of control samples estimated within the same assay and calculated as:

$$CV(\%) = \text{Standard deviation}/\text{mean} \times 100\%.$$

10 It was found to be between 1.5% and 3.5%. Inter-assay variation was calculated according to the same formula, based on estimations of aliquots from the quality-control pool in every assay run and was found to be between 2.6% and 8.4% (Table 1).

Table 1 – Intra- and Inter-assay Variation of PP-13 ELISA

15

PP-13 level pg/ml	Intra-assay variation (CV, %) (n = 16 each)	Inter-assay variation (CV, %) (n = 8 assays)
20	1.54	4.61
50	3.51	8.39
100	2.01	4.64
200	1.91	2.56

#### (c) PP-13 levels in human blood serum

Two-monoclonal antibody sandwich ELISA was employed for PP-13  
 20 measurement in blood serum of men, non-pregnant and pregnant women. It was found that PP-13 level in pregnant women was significantly higher (225.8 $\pm$ 100.5 pg/ml) than detected concentrations in non-pregnant women (17.1 $\pm$ 45.9 pg/ml) or in men (6.8  $\pm$  13.1 pg/ml). Many samples from men and non-pregnant women showed zero level of PP-13. These results suggest



that PP-13 is a real placental protein and that two-antibody sandwich ELISA of PP-13 may be used as a screening tool in pregnant women.

### References

1. Bohn. H., Winckler, W., Grundmann. U.. Immunochemically detected  
5 placental proteins and their biological functions. *Arch. Gynecol. Obstet.*,  
249:107-118 (1991).
2. Rutanen, E., Bohn, H., Seppala. M., Radioimmunoassay of placental  
protein 12: levels in amniotic fluid, cord blood, and serum of healthy  
adults, pregnant women and patients with trophoblastic disease. *Am. J.*  
10 *Obstet. Gynecol.*, 144:460-463 (1982).
3. Howell, R.J.S., Economides, D., Teisner, B., Farkas. A.G., Chard, T.,  
Placental proteins 12 and 14 in pre-eclampsia, *Acta, Obstet. Gynecol.*,  
*Scand.*, 68:237-240 (1989).
4. Scherbakova, L.A., Gocze, P.M., Olefirenko, G.A., Than, G.N.,  
15 Szabo, D.G., Petrulin, D.D., Tatarinov, Yu. S., Csaba. I.F., Comparative  
study of enzyme-linked immunosorbent assay and radioimmunoassay  
techniques in determining serum placental protein 14 levels in  
gynecologic patients. *Tumor Biol.*, 12:267-271 (1991).
5. Giulian, G.G., Moss R.L., and Greaser, M., Improved Methodology  
20 for Analysis and Quantitation of Proteins and one-dimensional  
silver-stained gel. *Anal. Biochem.*, 129:277-287 (1983).
6. Eshhar, Z., Blatt, C., Bergman. Y., Haimovich. J., Induction of  
secretion of IgM from cells of the B cell line 38C-13 by somatic cell  
hybridization. *J. Immunol.*, 122:2430-2434 (1979).

**CLAIMS:**

1. A monoclonal antibody (Mab) capable of binding Placental Protein 13 (PP-13).
2. A Mab according to Claim 1 produced by a hybridoma cell selected  
5 from the group consisting of clones # 26-2, 27-2-3, 215-28-3, 534-16 and 606-8-11-67.
3. A hybridoma clone selected from the group consisting of clones # 26-2, 27-2-3, 215-28-3, 534-16 and 606-8-11-67.
4. An immunoassay for measuring the level of PP-13 in a biological  
10 fluid comprising the steps of:
  - (a) bringing said fluid into contact with a Mab according to Claim 1, thereby forming Mab-PP-13 complexes;
  - (b) exposing said complexes to a second antibody linked to a signal-generating molecule, said second antibody being capable of  
15 binding said complexes; and
  - (c) providing conditions conducive to the production of a signal generated by said signal-generating molecule.
5. An immunoassay according to Claim 4 wherein said Mab in step (a) is bound to a solid phase.
- 20 6. An immunoassay according to Claim 4 wherein said second antibody is also a Mab according to Claim 1.
7. An immunoassay according to Claim 4 wherein said signal generating molecule is an enzyme.
8. An immunoassay according to Claim 4 wherein said signal  
25 generating molecule is a ligand, and step (c) of claim 4 comprises incubating the product of step (b) with a ligand binding molecule linked to an enzyme.
9. An immunoassay according to Claim 8 wherein said ligand is biotin and said ligand-binding molecule is extravidin.

10. A kit for measuring the level of PP-13 in a biological fluid comprising

(a) a Mab according to Claim 1;

(b) a second antibody linked to a signal-generating molecule; and

5 (c) PP-13 standard solutions.

11. A kit according to Claim 10 wherein said Mab in step (a) is bound to a solid phase.

12. A kit according to Claim 10 wherein said second antibody is also a Mab according to Claim 1.


10 13. A kit according to Claim 10 wherein said signal generating molecule is an enzyme.

14. A kit according to Claim 10 wherein said signal generating molecule is a ligand, and said kit further comprises a ligand binding molecule linked to an enzyme.

15 15. A kit according to Claim 14 wherein said ligand is biotin and said ligand-binding molecule is extravidin.

1/18

# SDS-PAGE ELECTROPHORESIS OF MOUSE ANTI-PP-13 ASCITES & IgG



1. MW markers
2. Ascitic fluid #215-28-3
3. Purified IgG #215-28-3
4. Ascitic fluid #27-2-3
5. Purified IgG #27-2-3
6. Control (sample buffer)

Fig. 1

2/18

# TESTING OF MOUSE ANTI-PP-13 SERUM IN DIRECT ELISA (1st bleeding)




Fig. 2

3/18

### CLASSING OF ANTI-PP-13 ANTIBODIES IN DIRECT ELISA (1st screening)




Fig. 3

4/18

## TESTING OF ANTI-PP-13 ANTIBODIES IN SANDWICH ELISA (1st screening)




Fig. 4

5/18




Fig. 4 (Cont.)



6/18

## TESTING OF ANTI-PP-13 ANTIBODIES IN SANDWICH ELISA (cloning: 1st screen)




Fig. 5

7/18




Fig. 5 (Cont.)

8/18

## CLASSING OF ANTI-PP-13 ANTIBODIES IN DIRECT ELISA (cloning: 2nd scrn)




Fig. 6

9/18

# CLASSING OF ANTI-PP-13 ANTIBODIES IN DIRECT ELISA (cloning: 2nd scrn)




Fig. 7

10/18

# CLASSING OF ANTI-PP-13 ANTIBODIES IN DIRECT ELISA (cloning: 2nd scrn)




Fig. 8

11/18

## CLASSING OF ANTI-PP-13 ANTIBODIES IN DIRECT ELISA (cloning: 2nd screen)





Fig. 9

12/18

## CLASSING OF ANTI-PP-13 ANTIBODIES IN DIRECT ELISA (cloning: 3rd screen)

*Fig. 10*

13/18

## TWO-MONOCLONAL ANTIBODY SANDWICH ELISA IN DIFFERENT VARIANTS





Fig. 11



14/18





Fig. 11 (Cont.)

15/18




Fig. 12

16/18




Fig. 13

17/18




Fig. 14

18/18




Fig. 15

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IL 00/00196

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K16/18 C12N5/20 G01N33/577 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, CHEM ABS Data, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 198 366 A (SILBERMAN) 30 March 1993 (1993-03-30) claims 1-13 ---	1-15
A	US 4 500 451 A (BOHN ET AL) 19 February 1985 (1985-02-19) claims 1-3 ---	1-15
P,A	WO 99 38970 A (DIAGNOSTIC TECHNOLOGIES) 5 August 1999 (1999-08-05) claims 1-11 --- -/--	1-15

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 June 2000

Date of mailing of the international search report

12/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Le Flao, K

# INTERNATIONAL SEARCH REPORT

Int. Patent Application No.

PCT/IL 00/00196

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	<p>THAN N ET AL: "Isolation and sequence analysis of a cDNA encoding human placental tissue protein 13 (PP13), a new lysophospholipase, homologue of human eosinophil Charcot-Leyden crystal protein" PLACENTA (NOV. 1999) 20 (8) 703-10, XP000915077 abstract</p> <p>-----</p>	1-15

# INTERNATIONAL SEARCH REPORT

information on patent family members

Inter:      nal Application No

PCT/IL 00/00196

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5198366	A	30-03-1993	IL 78237 A		30-06-1991
			CA 1295939 A		18-02-1992
<hr/>					
US 4500451	A	19-02-1985	DE 3230996 A		23-02-1984
			AT 38521 T		15-11-1988
			AU 555699 B		02-10-1986
			AU 1816783 A		23-02-1984
			CA 1213213 A		28-10-1986
			DE 3378414 D		15-12-1988
			EP 0101603 A		29-02-1984
			JP 1693459 C		17-09-1992
			JP 3054680 B		20-08-1991
			JP 59059621 A		05-04-1984
<hr/>					
WO 9938970	A	05-08-1999	AU 2071799 A		16-08-1999
<hr/>					



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**